LPL Financial’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,664
| Closed | -$128K | – | 4816 |
|
|
2023
Q3 | $128K | Sell |
11,664
-4,000
| -26% | -$48.8K | ﹤0.01% | 4369 |
|
|
2023
Q2 | $202K | Sell |
15,664
-1,615
| -9% | -$21.2K | ﹤0.01% | 4146 |
|
|
2023
Q1 | $207K | Sell |
17,279
-591
| -3% | -$8.06K | ﹤0.01% | 4018 |
|
|
2022
Q4 | $245K | Sell |
17,870
-1,243
| -7% | -$18.2K | ﹤0.01% | 3817 |
|
|
2022
Q3 | $280K | Hold |
19,113
| – | – | ﹤0.01% | 3648 |
|
|
2022
Q2 | $290K | Sell |
19,113
-190
| -1% | -$2.91K | ﹤0.01% | 3652 |
|
|
2022
Q1 | $347K | Buy |
19,303
+10,865
| +129% | +$206K | ﹤0.01% | 3467 |
|
|
2021
Q4 | $201K | Sell |
8,438
-1,633
| -16% | -$45.4K | ﹤0.01% | 3980 |
|
|
2021
Q3 | $306K | Sell |
10,071
-2,321
| -19% | -$70.1K | ﹤0.01% | 3627 |
|
|
2021
Q2 | $395K | Hold |
12,392
| – | – | ﹤0.01% | 3363 |
|
|
2021
Q1 | $371K | Sell |
12,392
-784
| -6% | -$25.5K | ﹤0.01% | 3298 |
|
|
2020
Q4 | $418K | Sell |
13,176
-3,810
| -22% | -$114K | ﹤0.01% | 2912 |
|
|
2020
Q3 | $466K | Sell |
16,986
-318
| -2% | -$8.5K | ﹤0.01% | 2530 |
|
|
2020
Q2 | $469K | Sell |
17,304
-1,043
| -6% | -$25.6K | ﹤0.01% | 2449 |
|
|
2020
Q1 | $358K | Buy |
18,347
+688
| +4% | +$14.8K | ﹤0.01% | 2347 |
|
|
2019
Q4 | $414K | Sell |
17,659
-3,487
| -16% | -$73.8K | ﹤0.01% | 2527 |
|
|
2019
Q3 | $397K | Sell |
21,146
-479
| -2% | -$9.73K | ﹤0.01% | 2451 |
|
|
2019
Q2 | $457K | Sell |
21,625
-9,406
| -30% | -$194K | ﹤0.01% | 2342 |
|
|
2019
Q1 | $652K | Sell |
31,031
-35,796
| -54% | -$751K | ﹤0.01% | 1985 |
|
|
2018
Q4 | $1.26M | Buy |
66,827
+19,031
| +40% | +$397K | ﹤0.01% | 1363 |
|
|
2018
Q3 | $1.19M | Buy |
47,796
+2,310
| +5% | +$56.8K | ﹤0.01% | 1545 |
|
|
2018
Q2 | $1.1M | Sell |
45,486
-74,706
| -62% | -$2.01M | ﹤0.01% | 1561 |
|
|
2018
Q1 | $3.49M | Buy |
120,192
+77,718
| +183% | +$2.2M | 0.01% | 851 |
|
|
2017
Q4 | $1.01M | Buy |
42,474
+11,131
| +36% | +$281K | ﹤0.01% | 1525 |
|
|
2017
Q3 | $848K | Buy |
31,343
+10,619
| +51% | +$258K | ﹤0.01% | 1551 |
|
|
2017
Q2 | $477K | Sell |
20,724
-2,292
| -10% | -$51.8K | ﹤0.01% | 1918 |
|
|
2017
Q1 | $553K | Sell |
23,016
-2,461
| -10% | -$56.6K | ﹤0.01% | 1716 |
|
|
2016
Q4 | $551K | Sell |
25,477
-10,879
| -30% | -$250K | ﹤0.01% | 1672 |
|
|
2016
Q3 | $934K | Sell |
36,356
-361
| -1% | -$8.9K | 0.01% | 1250 |
|
|
2016
Q2 | $864K | Sell |
36,717
-47,047
| -56% | -$1.07M | 0.01% | 1276 |
|
|
2016
Q1 | $1.9M | Buy |
83,764
+34,226
| +69% | +$731K | 0.01% | 1233 |
|
|
2015
Q4 | $1.35M | Buy |
+49,538
| New | +$1.43M | ﹤0.01% | 1441 |
|
Other funds holding CNCR
OMC
PFS
BBPWM
LPL Financial's CNCR Position: Q4 2023 in Review
LPL Financial sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2023, closing a stake of 11,664 shares — an estimated $128K sold.
LPL Financial first reported a position in CNCR in Q4 2015 and held it in 32 quarters. The position peaked at $3.49M in Q1 2018. 13 funds tracked by Wall St. Rank hold CNCR as of Q4 2023.
- LPL Financial reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2023 after selling out during the quarter.
- LPL Financial sold 11,664 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2023, an estimated $128K.
- LPL Financial first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 32 quarters.
- LPL Financial's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $3.49M in Q1 2018.
- 13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2023.
Based on LPL Financial's 13F filing for Q4 2023, filed 14 Feb 2024.